FDA Drug Shortage Database
Morphine (Duramorph) shortage
The FDA Drug Shortage Database lists 12 of 30 morphine presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on October 31, 2017. 12 more presentations are on the list as available.
- Generic listed
- In shortage
- Boxed warning
- DEA Schedule II
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 1mg/1ml injection | 0 | 2 | 0 |
| 2mg/1ml injection | 3 | 1 | 0 |
| 4mg/1ml injection | 2 | 2 | 0 |
| 5mg | 0 | 0 | 1 |
| 5mg/10ml injection | 0 | 1 | 0 |
| 5mg/1ml injection | 1 | 1 | 0 |
| 8mg/1ml injection | 1 | 0 | 0 |
| 10mg | 0 | 0 | 1 |
| 10mg/10ml injection | 0 | 1 | 0 |
| 10mg/1ml injection | 2 | 1 | 0 |
| 10mg/1ml solution | 1 | 0 | 0 |
| 15mg tablet | 0 | 0 | 1 |
| 20mg | 0 | 0 | 1 |
| 25mg/1ml solution | 0 | 1 | 0 |
| 30mg | 0 | 0 | 1 |
| 30mg tablet | 0 | 0 | 1 |
| 50mg/1ml injection | 2 | 0 | 0 |
| 200mg/20ml injection | 0 | 1 | 0 |
| 500mg/20ml injection | 0 | 1 | 0 |
Which presentations are listed?
Limited or unavailable now (12)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01) | Hikma Pharmaceuticals USA, Inc. | Current posted November 3, 2017, updated September 18, 2026 | Unavailable; Demand increase for the drug |
| Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25) | Hikma Pharmaceuticals USA, Inc. | Current posted November 3, 2017, updated September 18, 2026 | Unavailable; Demand increase for the drug |
| Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Limited Availability; Other |
| Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated September 15, 2026 | Unavailable; Other |
| Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated September 15, 2026 | Unavailable; Other |
| Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated September 15, 2026 | Unavailable; Other |
| Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated September 15, 2026 | Unavailable; Other |
| Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated October 6, 2026 | Unavailable; Demand increase for the drug |
| Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Unavailable; Other |
| Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Unavailable; Other |
| Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25) | Hikma Pharmaceuticals USA, Inc. | Current posted November 3, 2017, updated September 18, 2026 | unavailable; Demand increase for the drug |
Listed now, available (12)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10) | Hikma Pharmaceuticals USA, Inc. | Current posted November 3, 2017, updated September 18, 2026 | Available |
| Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10) | Hikma Pharmaceuticals USA, Inc. | Current posted November 3, 2017, updated September 18, 2026 | Available |
| Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01) | Hikma Pharmaceuticals USA, Inc. | Current posted November 3, 2017, updated September 18, 2026 | Available |
| Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02) | Piramal Critical Care Inc. | Current posted October 31, 2017, updated September 15, 2026 | Available |
| Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02) | Piramal Critical Care Inc. | Current posted October 31, 2017, updated September 15, 2026 | Available |
| Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1) | Amphastar Pharmaceuticals, Inc. | Current posted December 6, 2018, updated October 5, 2026 | Available |
| Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01) | Fresenius Kabi USA, LLC | Current posted October 31, 2017, updated October 6, 2026 | Available |
| Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25) | Hikma Pharmaceuticals USA, Inc. | Current posted November 3, 2017, updated September 18, 2026 | Available |
| Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
| Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12) | Hospira, Inc., a Pfizer Company | Current posted October 31, 2017, updated September 22, 2026 | Available |
Resolved or discontinued (6)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Morphine Sulfate, Suppository, 10 mg (NDC 0574-7112-12) | Padagis US LLC | To Be Discontinued posted July 23, 2026, updated July 23, 2026 | not given |
| Morphine Sulfate, Suppository, 20 mg (NDC 0574-7114-12) | Padagis US LLC | To Be Discontinued posted July 23, 2026, updated July 23, 2026 | not given |
| Morphine Sulfate, Suppository, 30 mg (NDC 0574-7116-12) | Padagis US LLC | To Be Discontinued posted July 23, 2026, updated July 23, 2026 | not given |
| Morphine Sulfate, Suppository, 5 mg (NDC 0574-7110-12) | Padagis US LLC | To Be Discontinued posted July 23, 2026, updated July 23, 2026 | not given |
| Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11) | Upsher-Smith Laboratories, LLC | To Be Discontinued posted December 22, 2025, updated December 22, 2025 | not given |
| Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11) | Upsher-Smith Laboratories, LLC | To Be Discontinued posted December 22, 2025, updated December 22, 2025 | not given |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
Are medicines for the same conditions short too?
Medicines whose labels share an indication with this one, and their own shortage status; listed as records, not substitutes.
| Medicine | Shared indication | Shortage | Generic labelers | Pharmacy cost |
|---|---|---|---|---|
| Acetaminophen and hydrocodone | Pain | No current entry | 36 labelers | $0.152 per tablet 10-325 mg tablet |
| Oxycodone | Pain | No current entry | 32 labelers | $0.0884 per tablet 5 mg tablet |
| Acetaminophen and oxycodone | Pain | A presentation being discontinued | 29 labelers | $0.183 per tablet 7.5-325 mg tablet |
| Tramadol | Pain | No current entry | 39 labelers | $0.0248 per tablet 50 mg tablet |
| Acetaminophen and codeine | Pain | No current entry | 24 labelers | $0.256 per tablet 3 tablet |
| Hydromorphone | Pain | In shortage | 13 labelers | $0.219 per tablet 4 mg tablet |
| Methadone | Pain | No current entry | 18 labelers | $0.177 per tablet 10 mg tablet |
| Oxymorphone | Pain | No current entry | 9 labelers | n/a |
| Tapentadol | Pain | No current entry | 4 labelers | $14.48 per tablet 100 mg tablet |
| Hydrocodone | Pain | No current entry | 1 labeler | $7.95 per capsule 15 mg capsule |
| Acetaminophen and tramadol | Pain | No current entry | 11 labelers | $0.116 per tablet 37.5-325 mg tablet |
| Levorphanol | Pain | No current entry | 7 labelers | $10.65 per tablet 2 mg tablet |
Source: FDA drug labels, FDA Drug Shortage Database, NDC Directory, CMS NADAC of October 7, 2026 (FDA files October 8, 2026)
What next?
- Every shortage now
- medicines by presentations in shortage